A Chicago biotech claims in a new lawsuit that Cambridge venture capital firm Third Rock Ventures and bluebird bio CEO Nick Leschly worked to hinder its drug development efforts so it could more easily obtain a key part of its intellectual property.

Errant Gene Therapeutics is suing Third Rock Ventures and Leschly three years after it sued New York-based Sloan Kettering Memorial Cancer Center over a stalled rare disease trial.

In the lawsuit, filed on Friday in Suffolk County Superior Court, Errant…

Boston Biz Journal https://www.bizjournals.com/boston/news/2019/06/13/chicago-biotech-sues-third-rock-bluebird-bio-ceo.html?ana=RSS&s=article_search